BMS Presents Results of Opdivo (nivolumab) + CT or Yervoy (ipilimumab) in P-III CheckMate -648 Trial for Unresectable Advanced or Metastatic ESCC at ASCO 2021

Shots:

• The P-III CheckMate -648 trial evaluating Opdivo + CT or Opdivo (3 mg/kg, q2w) + Yervoy (1 mg/kg, q6w up to 24mos.) in patients with unresectable advanced or metastatic ESCC
• Results: Both combinations showed OS benefits over CT in PD-L1 positive & all-randomized populations, m-OS for Opdivo + CT (13.7 vs 9.1 mos. & 13.2 vs 10.7 mos.) & for Opdivo + CT (3.7 vs 9.1 mos. & 2.8 vs 10.7 mos.); mDoR (8.4 vs 11.8 mos.) & 5.7 mos. for CT alone; ORR (53% vs 35%) & 20% for CT alone
• Additionally, Opdivo + CT showed improvement in PFS with an m-PFS (6.9 vs 4.4 mos.) while Opdivo + Yervoy failed to meet its 1EPs of PFS, safety profiles were consistent with previously reported for other tumors

Click here to­ read full press release/ article | Ref: Businesswire | Image: Fierce Pharma